Publications by authors named "Wesley H Anderson"

Claim this Profile
F
Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice.
Anna E Martin, Douglas A Schober, Alexander Nikolayev, Vladimir V Tolstikov, Wesley H Anderson

CNS Neurol Disord Drug Targets· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.
Shannon L Risacher, Wesley H Anderson, Arnaud Charil, Peter F Castelluccio, Sergey Shcherbinin

Neurology· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu receptor antagonist.
Jeffrey M Witkin, Paul L Ornstein, Charles H Mitch, Renhua Li, Stephon C Smith, Wesley H Anderson

Neuropharmacology· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis.
Kjell A Svensson, Beverly A Heinz, John M Schaus, James P Beck, Junliang Hao, Wesley H Anderson

J Pharmacol Exp Ther· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8 Through Investigations of TARP γ-8 Null Mice§.
Scott D Gleason, Akihiko Kato, Hai H Bui, Linda K Thompson, Sabrina N Valli, Wesley H Anderson

CNS Neurol Disord Drug Targets· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Linda M Rorick-Kehn, Jeffrey M Witkin, Michael A Statnick, Elizabeth L Eberle, Jamie H McKinzie, Wesley H Anderson

Neuropharmacology· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis